BioSpace News Archive

ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc. and Merck Animal Health are proud to announce a groundbreaking partnership with The United States Equestrian Federation to advance animal health through innovative products and technologies.

Halberd Corporation announced Mississippi State University has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd’s groundbreaking patent-pending nasal spray.

Celularity Inc. announced that it has received a $45 million purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store.

Integral Molecular, a leader in providing safe, off-the-shelf Reporter Virus Particles to study vaccine efficacy, has expanded its extensive portfolio with RVPs for influenza strains recently recommended by WHO for 2023/2024 seasonal influenza vaccines.

PharmaEssentia USA Corporation announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been updated to include BESREMi® as a preferred therapeutic option for the treatment of adults with both high and low-risk polycythemia vera, regardless of treatment history.

MEI Pharma, Inc. today announced an update to the Phase 1 study evaluating voruciclib, an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor, in patients with relapsed and refractory (“R/R”) acute myeloid leukemia (“AML”) or B-cell malignancies.

Forge Biologics, a leading manufacturer of genetic medicines, announced today that it has joined the Bespoke Gene Therapy Consortium (BGTC), a public-private collaboration to accelerate the delivery of promising new gene therapies to patients with rare diseases.

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced the publication of two-year results of the ROMEO study in Clinical Ophthalmology.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, announced that a leading pharmaceutical company in Brazil selected ValGenesis iRisk to redefine and automate the company’s risk-based validation processes.